Hello, and welcome to AMETEK's Second Quarter 2025 Earnings Conference Call. [Operator Instructions] I would now like to turn the conference over to Kevin Coleman, Vice President of Investor Relations and Treasurer. Sir, you may begin.

Thank you, Towanda. Good morning, and welcome to AMETEK's Second Quarter 2025 Earnings Conference Call. Joining me today are Dave Zapico, Chairman and Chief Executive Officer; and Dalip Puri, Executive Vice President and Chief Financial Officer. During the course of today's call, we will be making forward-looking statements, which are subject to change based on various risk factors and uncertainties that may cause actual results to differ significantly from expectations. A detailed discussion of the risks and uncertainties that may affect our future results is contained in AMETEK's filings with the SEC. AMETEK disclaims any intention or obligation to update or revise any forward-looking statements. Any references made on this call to 2024 or 2025 results will be on an adjusted basis, excluding after tax, acquisition-related intangible amortization, and excluding the pretax $29.2 million or $0.10 diluted share charge in the first quarter of 2024 for integration costs related to the Paragon Medical acquisition. Reconciliations between GAAP and adjusted measures can be found in our press release and on the Investors section of our website. We'll begin today's call with prepared remarks, and then we'll open it up for your questions. I'll now turn the meeting over to Dave.

Thank you, Kevin, and good morning, everyone. AMETEK delivered strong second quarter results, highlighted by record level sales and EBITDA, strong core margin expansion and excellent earnings growth. We also raised our full year sales and earnings guidance to reflect our second quarter results and the recent acquisition of FARO Technologies. The addition of FARO Technologies nicely complements our existing metrology and precision measurement businesses. Our ability to deliver strong operating performance is notable given the challenging macro environment and is a testament to the quality of our differentiated businesses, the strength of our operating capabilities and the contribution from all AMETEK colleagues. Now let me turn to our second quarter financial results. Sales were a record $1.78 billion, an increase of 2.5% from the second quarter of 2024. Organic sales were flat. Acquisitions added 1.5 points and foreign currency translation was a 1-point benefit. Book-to-bill in the quarter was 1.00 and we ended the second quarter with a backlog of $3.47 billion near record levels. Our operating performance in the quarter was excellent, leading to strong margin expansion and earnings growth. Operating income in the quarter was $462 million, a 3% increase over the second quarter of 2024. The operating margins were 26% in the quarter, up 20 basis points from the prior year. Core margins, excluding the dilutive impact from acquisitions and the impact of foreign currency, were very strong at 26.7%, up 90 basis points versus the prior year. EBITDA in the quarter was a record $565 million, up 4% versus the prior year with EBITDA margins an impressive 31.8%. This operating performance led to earnings of $1.78 per diluted share, up 7% versus the second quarter of 2024. Now let me provide some additional details at the operating group level. First, the Electronic Instruments Group. The…

Thank you, Dave, and good morning, everyone. As Dave noted, AMETEK had a solid second quarter, highlighted by excellent operating performance, robust core margin expansion and strong earnings growth. Now let me provide some additional financial highlights for the second quarter. Second quarter general and administrative expenses were $27 million or 1.5% of sales, in line with last year's second quarter. Second quarter interest expense was $17 million. Second quarter other expense was higher by approximately $3 million versus the prior period due to lower pension income and foreign exchange movements. The effective tax rate in the quarter was 19%, in line with the second quarter of 2024. For 2025, we now anticipate our effective tax rate to be between 19% and 19.5%. As we have stated in the past, actual quarterly tax rates can differ dramatically, either positively or negatively from this full year estimated rate. The recently enacted tax reconciliation bill aligns well with our U.S.-based manufacturing footprint and innovation-led growth model. While we are continuing to assess the full implications, we expect it to favorably impact our cash tax position. Capital expenditures in the second quarter were $29 million and we now expect capital expenditures to be approximately $160 million for the full year or about 2% of sales. Depreciation and amortization expense in the quarter was $108 million. For the full year, we expect depreciation and amortization to be approximately $425 million, including after-tax, acquisition-related intangible amortization of approximately $210 million or $0.91 per diluted share. Operating working capital in the second quarter was 18.6% of sales, in line with the second quarter of 2024. Operating cash flow was $359 million in the quarter, and free cash flow was $330 million. Year-to-date, free cash flow conversion was 102% of net income. For 2025, we continue to…

Thanks Dalip, Towanda, can we please open the line for questions?

[Operator Instructions] Our first question comes from the line of Deane Dray with RBC.

Can we start off with the end market and regional tour and given all of the fluid trading environment. It's really interesting to get your perspective on kind of the puts and takes. And Dave, could you also include the cadence of the months because we've heard reports recently where it was choppy month-to- month, and I know you've got some perspective there? We heard June was down but then July came back. I don't know if that was a pattern you saw. So a bit to unpack there.

Yes, I'll try to get all three of those, and I'll start with the tour around the company. Our overall sales for our Process businesses were flat year-over-year as contributions from recent acquisitions offset a 4% decline in organic sales. The trade dynamics and back-and-forth negotiations continue to create uncertainty and hesitation and project spending, but we remain very encouraged by a strong pipeline of underlying project activity across our businesses. And given this, we now expect organic sales for our Process businesses to be flat to down low single digits for the full year. Switching to Aerospace and Defense, our Aerospace delivered -- business has delivered another very strong quarter, with both overall and organic sales growth increasing high-single digits. Growth was broad-based across all subsegments in the quarter. All subsegments, I underline that with commercial OEM seeing the strongest growth. For the full year 2025, we now expect organic sales for our Aerospace and Defense businesses to be up high single digits. So we increased that from mid-single digits, feeling really good about that. Our Power businesses reported low-single-digit increase in both overall and organic sales for the quarter. Given our strong position serving energy, grid modernization, electrification applications, we're well positioned for long-term growth. And for the full year, we now expect organic sales for our Power & Industrial businesses to be up low-single digits compared to the prior year. So we increased that also from flat. So good strength in our A&D business, good strength in our Power and Industrial. And then finally, our Automation & Engineered Solutions returned to growth this quarter with both overall and organic sales up low single digits. We once again -- we saw strong orders growth across our Paragon business and our Automation businesses in the quarter. So excited about…

Great. Dave, that was a comprehensive answer to multipart questions, so I'll leave it there.

Our next question comes from the line of Jeffrey Sprague with Vertical Research.

Congrats on getting -- congrats on getting FARO done. I wonder if you could just talk about that a little bit more in terms of the integration plan. I believe you see a lot more synergies there than typical AMETEK playbook given their margins coming in and the fit with Creaform and other things. So maybe you could just elaborate on what you see on synergies. And then really tying it to the 2025 guide also. It doesn't look like really you're expecting much of a benefit in 2025. I know you'll be bedding it down, but if you're excluding restructuring, everything I would think maybe we do get some contribution in '25?

Yes, that's a great question, Jeff. I'll start with -- we think it will be a couple of penny benefit in 2025. So we have a partial quarter in Q3 and then Q4, so we think we'll pick up a couple of pennies there. When you take a step back and look at the acquisition, it's -- as I mentioned in my prepared remarks, it's an excellent fit with what we do. And we think we can add meaningful value to FARO. They were public companies. So we have the elimination of the public company costs and the integration into AMETEK's global infrastructure. And we have a little higher than typical synergies. We have a mid-teens cost synergy. So if you think about the FARO, the last couple of quarters has been operating at about 15% EBITDA, and we think that will be a 30% EBITDA in about 3 years. So a significant potential to expand operating margins through integration into the AMETEK infrastructure and operating model. And we're really pleased that we were able to add the highly differentiated adjacent products and technologies to AMETEK's Ultra Precision Technologies division. The products nicely complement ours. We have a leading market share now, #1 or #2 in many key verticals, measurement arms, laser scanners, laser trackers. We have now a new presence in fast-growing digital reality scanning market. We have an emerging SaaS solution, enabling the digital reality capture workflow. And they have a good recurring revenue profile for service. About 60% of its hardware, 25% of its service and 15% of the software. So -- and the teams have come in and done a great job. We're working very well together. So we're excited about it. When I look at this business, it reminds me a lot of the Zygo acquisition. Very similar Zygo and FARO name, but also it went into our UPT division, the same as Zygo. And if you look at Zygo, it was a smaller public company and they were always trying to swing for the fences hit grand slams because they want to get noticed and they took on some things that were outside of their core. And we've a very similar situation with FARO. And if I look at what we did with Zygo, the sales averaged 9% CAGR over the first 10 years. EBITDA grew over 5x. EBITDA margins increased 2.5x, and we reduced working capital by 50% over the first 5 years. So I think we have that kind of potential here. There's a lot of talent there need to give us some focus. The current management team did a good job. I'll call it, cleaning up the business in the last 12 or 18 months, and we're extremely excited of what the future brings.

So a pretty good algorithm if you can pull that off. That's great. And then maybe -- Yes, absolutely. And then on Paragon, Dave, if you could. So it sounds, as you said, order is firming up. Is that translated to the top line at Paragon yet? How do you see Paragon specifically performing here as we work through the back of the year?

Yes. I mean Paragon had another excellent quarter, Jeff. Orders growth was again robust. Sales were strong, and we continue to drive outstanding margin expansion. The orders were the largest increase in AMETEK by far. We also have a situation where the Paragon EBITDA margins are now in line with AMETEK. So they're a 30-plus percent EBITDA margins, and we see meaningful margin runway ahead. So outstanding work by the entire Paragon team that these talk is over, and we are very, very excited about what we're seeing. So very pleased with what's going on there. They're in a good position with our customers and consumable surgical instruments and plantable components and attractive market segments. And we're through the destock. We took some time to do some hard work cleaning up the business. It has excellent engineering capability. They have new programs wins and really, really pleased with where we're at now.

Our next question comes from the line of Jamie Cook with Truist.

Nice quarter. Two questions. First, Dave, as I look at your guide, I'm just trying to understand the puts and takes and I guess, level of conservatism in the guide because you're saying FARO adds a couple of pennies, it sounds like tariffs should be more of a tailwind. So can you help us understand what you're assuming now relative to the $100 million in tariff costs that you talked about last quarter and then the $70 million from China. And is there any change sort of in the core business? I just want to understand the puts and takes of the guide today versus first quarter. And then my second question is again, impressed with the EMG margins this quarter, Paragon, you're now saying the margins are in line with AMETEK just the setup for EMG margins as we exit the year. I would assume that would be one of your highest margin improvement segment -- the margins in that segment should improve the most. Just trying to understand if I'm thinking about that correctly?

Yes. I'll start with the margins. And I do think you're thinking about it correctly. I mean there's excellent performance in the quarter, up 200 basis -- 210 basis points on a reported basis, 260 on a core margin basis. So EMG really is -- had a good quarter in margins. And in the back half of the year, I think it's going to stay the same way. There's a good margin expansion there. And both our EIG and EMG businesses core margin expanded 90 basis points. The reported margins were up 20, but core was up 90. We had a fantastic quarter. We are excellent in driving the operations of the business. There was excellent productivity there was positive price/cost and really strongly performing acquisitions. When I look at the OpEx, I mean, our people are getting it done, we rose -- we raised our OpEx. We're going to -- working through the P&L to $155 million. That's about $25 million from where we started the year and up $5 million from last quarter. So the OpEx side of this thing is working extremely well, and we're pleased with that. Going back to the guide, we beat our earnings. We boosted our guide for the year, and we have a big bolt-on. And we talked about a couple of cents from FARO. And that's all built into the model. I think there's a bit of conservatism in the Q3 guide as we get through all these changing dynamics, we feel very confident, but there's a bit of conservatism in the near-term guide. I think that in terms of China, you mentioned the $70 million that we had flagged in the second quarter. We got a good portion of that. Later in the quarter, it opened up. We didn't get it all. We got a good portion of that. And the $70 million that we identified as a tariff impact that we would offset we're not going to constantly change with that changing environment. We're not going to constantly update the exposure, but what I'm telling in real time. But we got it. And we don't have a problem this year. So the $100 million that was a negative headwind is not a negative headwind. That's the best way I can explain it.

Our next question comes from the line of Matt Summerville with D.A. Davidson.

A couple of questions. You talked in detail about Paragon, which was very helpful. Can you go through the same kind of analysis specifically the Automation side of the business, where -- how that business is performing from a profitability standpoint? What you're seeing from an inbound order point of view? Where you are with the inventory sort of reductions you were seeing in the channel there as that's been one of the more challenged businesses for you guys? And then I have a follow-up.

Yes. Yes. The Automation business it's in the same category as Paragon as the destock is over. And we're seeing strong growth in orders. There's a -- Paragon and the automation business drove the profitability increase. And EMG. So there's continued upside there. But both Paragon and Automation, the 2, the medtech which Paragon's in, Automation that dealt with the destock is done. So we're feeling good about that. It's driving profit growth and that's why the EMG margins are up 260 basis points on a core basis. And then you have a follow up?

Yes. Yes. As you think about those businesses specifically, what do you think the right go-forward organic algorithm looks like for that portion of AMETEK. And then, Dave, if you can just maybe comment a little more broadly what you're seeing from a go-forward actionability standpoint, M&A-wise, post FARO, what you're seeing in terms of deal size multiples, et cetera, that would be helpful.

Yes. I think the EMG business is -- the automation and engineered part of EMG is inflecting up. So I think it's is going to lead us in our next phase of growth. And I think we don't -- we're saying this year that we'll be up mid-single digits. So I think that's positive from last year. And obviously, if the order rates continue, there can be some upside there. In terms of the acquisition pipeline, this year, we got 2 deals done deployed $1 billion and acquired $400 million in revenue, and we're excited about these acquisitions. They are high-quality businesses that expand our presence in attractive growth markets. We have a clear path to add value in both the businesses. I talked about the recent acquisition of FARO in detail. And to your question, our pipeline remains strong. We're very actively looking at a number of high-quality deals. As Dalip mentioned, we have $2 billion of existing cash and credit facilities. As always, we're going to remain disciplined, but we did some analysis. And if we levered up to 2.5x, they got about $4.5 billion to $5 billion to spend. And I think that we have the opportunity to differentiate our performance with the M&A element of our growth strategy, combined with our balance sheet and combined with our strong cash flow. So we excelled at this and especially when markets are choppy and the combination of our operational excellence and M&A, I think we're really focused on the pipeline and the pipeline is strong.

Our next question comes from the line of Chris Snyder with Morgan Stanley.

I wanted to just kind of follow up on some of the commentary on back half growth. It seems like with FARO and some of the prior M&A done, that M&A could be about almost a mid-single-digit tailwind. And I would imagine there's some FX tailwinds on top of that kind of pushing collectively maybe into that mid- to high single-digit range in the back half. So I guess, is that right? And then what do you guys assume for organic growth into the back half of the year?

The one thing, Chris, talk about FX a little bit. And we're going to see for the year a top line FX tailwind and of about 1 percentage point. And we saw that same 1 percentage point in Q2. So on the top line, there's a little bit of a tailwind. But on the bottom line, we're largely naturally hedged. I mean when the currencies go either way, you never hear us talking about it. You never hear us as a positive from it. You're never negative from it. And we've run our businesses differently than most. And we have a natural hedge at the bottom line given the general balance of revenues and costs across key currencies. So generally, we don't see a meaningful impact to our profit results from FX movements. Now the FX is a dollar has weakened, and we do export quite a bit of high-technology products from the U.S. So I think the lower dollar because we build our higher tech technology products, and many of them in the U.S. is going to make us more competitive. So we understand our competitive positions. We're very well positioned to deal with currency fluctuations and it's a positive situation. Yes, I think organic growth for the year is still plus LSD. So we're assuming positive LSD. We're assuming both groups are positive, and then we got the acquisitions that get us to MSD for the year. So that's where we are versus our prior guide. And we think that it's reflective of the situation that we're operating in.

I appreciate that. And then maybe just following up on FARO. I think the margin opportunity is pretty clear when we see the gross margin that they were running at, but I think if we look at the business, there really hasn't been much, if any, growth over the medium to long term. Could you just maybe talk about how Creaform has grown? Just to provide some color on the industry growth there.

Yes. Creaform has grown like a weed when we acquired it, it was about a $40 million business, and it's grown at double digits since then, and the team has done an excellent job. So it's a much, much bigger business than when we acquired it. I made the analogy to our Zygo acquisition because I think it's really key. There's a lot of capability at FARO and a lot of talent, and they were just unfocused. They went down a path and spent a lot of money and didn't get a return for it. And we're going to do the same thing we did with Zygo as. We get the team together. We're going to focus on their core advantages. We're not going to swing for the fences. We're going to look for incremental wins and that business is going to grow nicely for us. So we have a bottom line chance to double the EBITDA margins in 3 years. And at the same time, with the technology and capability in that business, we're going to grow the top line, too, and we have a good analogy with the Zygo acquisition.

Our next question comes from the line of Andrew Obin with Bank of America.

Just two questions for me, and I'll stick them into one. In terms of China, was there any pull forward of demand on metrology equipment, given that there is still some uncertainty about pity tariffs in the second half? And just overall on your organic growth as -- and I apologize, I might have missed some stuff. But as you went through the segments and where you were and where you're going, is it fair to say that generally, you think short cycle industrial has bottomed, and you've raised your organic growth expectations on the margins going forward. Just want to button up those two issues.

Yes. In terms of China yes, the country was down low single digits for us for the quarter. So it was down a bit. I don't think there's really a pull ahead there. It's a situation where we're doing some projects and the projects require funding and the tariffs have just caused a lot of delays in getting the proper funding. So there's still strong demand for our projects, and we got a good portion of the stuff out in the second quarter that we flagged last time, so that was a positive. And there's still a bit of uncertainty in the market. And -- but we're well positioned, and our customers are working with us. And -- but I wouldn't characterize it as a pull ahead in metrology. No, I don't think we saw that. Your other question was related to?

Has the cycle bottomed and are you guys feeling better about organic growth?

Yes. yes. I think, yes, I don't characterize the med tech market and the automation market is short cycle, they're more mid-cycle. But we are seeing a specific destock end and we're feeling really good about the orders there. So that's true. So yes, I mean I think that where we're at is our strength in our A&D business, broad-based improved outlook. Our power business is starting to accelerate with grid spending, improved outlook. I think we talked about the automation and Engineered Solutions, Paragon, strong growth, highest in the company. Also our automation business now inflecting upward. And our process business, process and analytical is definitely not incrementally weakening, but the markets are still sluggish. And we have a pipeline of potential orders is solid. We're beginning to see quotations there related to reshoring related to new opportunities related to existing opportunities -- but that's where the project business is dealing with a bit of uncertainty. So we have to work our way through that. But in the other 3 market segments, it feels like we're in a positive situation. .

Our next question comes from the line of Brett Linzey with Mizuho.

Wanted to come back just to the slower decision-making. I guess are customers giving you any sense on the timing of that quotation activity and what the budgeting time line might look like there. And then anything on that front to glean through July in terms of those discussions.

Yes. Yes, the time lines -- yes, they are -- it's difficult. I mean there are definitely some delayed shipments. I think the certainty around the trade back and forth is important to get it resolved. So we're seeing the high number of trade deals get negotiated, get concluded. That takes the uncertainty off the table with tributary and we can go forward. So I don't think it's the -- the level of the tariffs is the uncertainty of the tariffs. And I think as we rapidly got some trade deals done, I think that uncertainty is reducing. So -- but as those play through and we understand the impacts of them, I think the uncertainty is going to reduce I mean, in the U.S., we have the overall positive outcomes, as Dalip mentioned, from the tax bill. So we have the -- it helped clarify those go-forward tax rules -- but the immediate expensing of R&D, the capital equipment -- for capital equipment purchases, the spur customer capital investments. And at the same time, we have the tariffs where we have people looking to reshore to the U.S., and we're in a very good position to help them do that. So I mean, that's a positive. And we have the -- but the tariffs have to get settled. And as we move through this and more of those get settled, I think the cloud is going to be removed from some of those projects.

And then just a follow-up on the $70 million of the potential at-risk revenue that you had flagged on the last quarter call. I know that's direct U.S. to China instrumentation. Maybe just a finer point on -- how much of that did ship in 2Q? And are you assuming that the remaining gets delivered as part of the framework? Or is there still some contingency there?

I think I'd say that a good majority of it shipped, and there's still some of it that's unresolved and that will get resolved in Q3 and Q4.

Okay, great. Best of luck.

Thank you.

Our next question comes from the line of Christopher Glynn with Oppenheimer & Company.

Dave, a question about the pipeline with a little bit more specificity on the aero defense market. Been a while since you did Abaco 4 years ago. I'm curious about the pipeline there, maybe the -- all the noise around the industry supply chain being picked up is revealing some properties there that might be opportunistic in that space. How are you thinking about -- and also how you're thinking about A&D more fundamentally in the context of all your businesses for long-term M&A?

Yes. I think the A&D market is certainly a market we would like to deploy more capital in. So we're actively looking at the market. We're actively looking at some deals. And from my viewpoint, it's been a great profit generator from AMETEK. We have unique differentiated positions a really good management team. They continue to perform, and I love to deploy capital in that area.

Okay. Great. And then for EMG, our automation is starting to accelerate here and it sounds like some incremental inflection. So with this cyclical momentum there and medical, would you expect more level loaded the first half, second half sales versus usually, it's slightly tilted towards the first half on a seasonal basis?

Yes. I'd say with the increase in orders, we're going to have a solid second half. So there might be a little bit of a different tilt than a typical year. You saw the orders coming in, in the first half of the year and you might have the shipments coming out 3 to 6 months later. So it might be a little bit different. .

Our next question comes from the line of Steve Barger with KeyBanc Capital Markets. .

This is Jacob Moore on for Steve. Just a two-parter from us as well kind of staying on orders and backlog, they look pretty solid this quarter. Can you just help us understand the breakdown of orders and backlog between the segments? Are there any end markets you would call out notable strength or weakness in orders? And then the quick second is related to the tariff situation. Beyond the China metrology, do you think there's any level of pull forward more broadly up to this point? Any perspective you have there would be helpful.

Yes. In terms of the pull forward, we're typically manufacturing customized systems that are higher dollar value. So I'm sure there was a little bit of pull forward, but it's not of a meaningful quantifiable number in our respect. So we are probably less affected by pull forwards than most companies because of the nature of our product portfolio. In terms of the orders, overall orders we're up 6% in the quarter. The EMG business was up double digits. EIG was up single digits in terms of book-to-bill was 1, EMG was a little above 1 and EIG was a little below 1. So it's -- and as I mentioned, the cadence of the orders, June was the strongest quarter of the -- strongest month of the quarter and also the strongest month of the year.

Our next question comes from the line of Nigel Coe with Wolfe Research.

A lot of details already. Dave, thanks for the details by segment. So the EIG book-to-bill, I'm just curious, the Aerospace and Defense businesses within EIG, will they be still above 1 within that overall?

Yes, they'd be above 1, but that's a backlog business, okay? So a lot of those orders are 3, 6 or 9 months even a year in advance, but yes, they were above 1.

Yes. Okay. And then you called out obviously the process and Analyticals, SBU, still, I think you said sluggish. There's been a lot of concern around academic and government funding. So just curious what you're seeing in your Gatan and some of the other businesses that might be affected by those pressures.

Yes, it's a good question. If you just look at our verticals, the medtech was positive. A&D, as I talked about, was positive. Automation was positive and food was positive. And the two negatives will be the semiconductor market and the research academia market. And it will be in the U.S. and globally. So that would be how I would look at it from the verticals. And obviously, our process business plays in a lot of those, but semi and research were headwinds in the quarter.

And maybe just could you just size that research exposure for AMETEK? And do you view these pressures as temporary? Or do you think it could be with us for some time?

Yes. research market is about 10% of AMETEK. That's a good estimate for size. In the U.S., you had -- there is a the redefining a little bit of the spend and the -- without getting into a lot of details, the spend associated with the projects have been reduced, but they still want to go forward with the projects. There are some delays. And those delays are happening. . I think that those -- in the research market, there are some parts of the world where the research market is very strong, about 25% to 30% of our research markets in the U.S. the balance of it internationally. So we had a little issue in China there that we talked about, and the smaller part of it is in the U.S. where there is some delay in research academia funding and we're seeing that as a bit of a headwind to our process business. I think it will be around for definitely in quarter 3 as we get into the fourth quarter, I'm not sure.

Our next question comes from the line of Scott Graham with Seaport Research Partners. .

I have -- I'm sorry, I joined the call late. Dave, did you provide what the pricing was in the quarter? And then I'll ask maybe what your thinking is for the second half. And then with that, with tariffs coming down, how did you approach that with customers? Because I'm sure prices announced were a certain level and then tariffs came down, you might have had to adjust those. Could you just kind of walk us through all that?

Yes. A lot of that is into the detailed discussions in our business units. I'll say that in the quarter, we had positive price cost spread. We didn't guide to a price exactly, but we had a positive price/cost spread. I think we'll have that for the year. The price increases, I would define them as selective. We're trying to work with our customers. . At the same time, I'm confident that the impacts of tariff and inflation will be offset by price. And it speaks to the results are related to the highly differentiated nature of the AMETEK product portfolio and our leadership position in niche markets around the globe. So that's how I'd characterize it.

Okay. I appreciate that. And then just maybe flipping to process, which looked like it was softer than perhaps you were thinking internally. That sort of division whatever we want to call that has a lot of different end markets. Could you kind of tell us what the puts and takes were there?

Yes. I was going through that a little bit before. So there would be positives on the medtech space, like our Rauland businesses there. They had a really good quarter, positive in the food business. We have a MOCON business, that's we have about 3% or 4% of our businesses so that was very positive. The oil and gas market, that was kind of just -- nothing really positive, nothing really negative. And in the semiconductor and the research markets, those were headwinds. So that's how I'd characterize it.

Ladies and gentlemen, I'm showing no further questions in the queue. I would now like to turn the call back to Kevin for closing remarks.

Thank you, Towanda, and thanks, everyone, for joining our call today. And as a reminder, a replay of today's webcast can be accessed in the Investors section of ametek.com. Have a great day.

Ladies and gentlemen, that concludes today's conference call. Thank you for your participation. You may now disconnect.